

## **CME AND FACULTY INFORMATION**

### **CME INFORMATION**

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Wisconsin Medical School and MDG/HBV *Watch*<sup>®</sup>.

The University of Wisconsin Medical School designates this continuing medical education activity for a maximum of 0.75 hour in category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours that he/she actually spent in the educational activity.

Please complete the CME Evaluation Form on the next page and fax it to Mary-Beth Infante at 908-879-7906 in order to receive your credit.

We are grateful for the independent educational grant provided by Bristol-Myers Squibb Company in support of this educational activity.

### **FACULTY INFORMATION AND DISCLOSURE**

Dr. Perrillo is the Director of Academic Affairs, Section of Gastroenterology and Hepatology, at the Ochsner Clinic Foundation in New Orleans. He graduated from Georgetown University School of Medicine, Washington D.C., in 1970 and completed his medical residency as well as GI fellowship training at Barnes Hospital, Washington University School of Medicine in St. Louis, MO. Before coming to Ochsner Clinic Foundation in 1994, Dr. Perrillo was a professor of medicine at Washington University and Director of the Gastroenterology Section of the St. Louis Veterans Affairs Medical Center. He has played a strategic role in the activities of the American Association for the Study of Liver Diseases (AASLD), being named as Chairman of the 59<sup>th</sup> Anniversary Endowment Campaign in 2000. He is currently Chairman of the Fund Development Committee and a participating member of the ethics and nominating committees of this international organization. He has served as the Head for the Section of Gastroenterology and Hepatology at Ochsner Clinic Foundation during 1994-2003 and is currently the Director of Academic Affairs for the Section.

Dr. Perrillo has authored more than 160 papers on viral hepatitis, having published as the principal author in *New England Journal of Medicine*, *Gastroenterology* and *Hepatology* and is internationally recognized for his work in antiviral therapy of chronic hepatitis B. He has been a prominent speaker and opinion leader in this area, having been invited to participate in both the NIH sponsored symposium on hepatitis B in 2000 and the recent EASL consensus conference on the management of hepatitis B. Dr. Perrillo has had extensive experience with interferon, adefovir and other nucleosides in the management of hepatitis B. He is currently the principal investigator in several clinical research programs on the combined use of interferon and nucleoside analogue treatment of chronic hepatitis B.

Dr. Perrillo will discuss commercially available products during his lecture. His presentation will also reference unlabeled/unapproved uses of drugs or products.

Dr. Perrillo has received grant support from GlaxoSmithKline and Roche Laboratories. He also serves as a consultant to Gilead, Roche and Bristol-Myers Squibb.

## **“Treatment Approaches and Practice Guidelines for the Management of HBV Infection”**

### **A CME-accredited Guest Web Lecture**

#### **CD--CME Activity – Quiz**

To receive the 0.75 category I credit of CME credit, you must complete the following quiz satisfactorily (70% correct answers) and record your answers at the bottom of the CME Web Activity Evaluation Form which follows the quiz:

**\*Please circle the correct response**

1. Long-term goals of treatment of hepatitis B include all of the following EXCEPT:
  - a. Achieving durable HBV DNA suppression
  - b. Preventing cirrhosis and hepatocellular carcinoma
  - c. Treating hepatocellular carcinoma
  - d. Prolonging survival
2. The AASLD Practice Guidelines have been recently updated and published in 2004, and they contain major therapeutic changes (SELECT ONE):
  - a. True
  - b. False
3. According to the AASLD Guidelines, patients who are HBeAg-negative, HBV DNA-positive and have ALT levels  $>2 \times$  ULN should be (SELECT ONE)::
  - a. Observed
  - b. Treated
4. Special groups of patients where more data are needed in order to develop specific treatment guidelines include (SELECT THE BEST ANSWER):
  - a. Co-infection with HDV, HIV, HCV
  - b. Immunosuppressed patients
  - c. Patients with extrahepatic disease
  - d. All of the above
5. Some of the pros of treatment of HBV with nucleoside analogues include all of the following EXCEPT:
  - a. Oral administration
  - b. Development of drug-resistant mutants
  - c. Utility in decompensated cirrhosis and post-OLT
  - d. Minimal side effects
6. The incidence of development of drug resistance with lamivudine at 3 years is (SELECT ONE):
  - a. 49%
  - b. 20%
  - c. 37%
7. Potential benefits of combination nucleoside analogues for treatment-naïve patients with HBV include all of the following EXCEPT::
  - a. Additive or synergistic antiviral effects
  - b. Potential to prevent or delay development of drug resistance
  - c. More rapid HBV inhibition and clinical stabilization

d. Cost effective approach

8. In the CALM Study, reported by YF Liaw and colleagues in *Hepatology* in 2003, time to disease progression in patients with both wild-type and YMDD mutant CHB was significantly lower in lamivudine-treated patients versus placebo-treated patients (SELECT ONE):
- True
  - False
9. In a study by P Marcellin and colleagues assessing HBV DNA response and normal ALT levels in patients receiving peginterferon alfa-2a + placebo versus peginterferon alfa-2a + lamivudine versus lamivudine alone, the best response was seen in patients receiving lamivudine alone(SELECT ONE):
- True
  - False
10. In a study by WG Cooksley and colleagues reported in the *Journal of Viral Hepatitis* in 2003, the end-of-follow-up HBeAg response to peginterferon alfa-2a at a dose of 180 µg/wk was (SELECT ONE):
- 25%
  - 35%
  - 20%
  - 32%



29582

# CME WEB ACTIVITY EVALUATION

## *Treatment Approaches and Guidelines for the Management of HBV Infection*

**1. Please evaluate this educational activity as a whole by filling in the appropriate circle:**

	Excellent	Very Good	Good	Fair	Poor
USEFULNESS	⑤	④	③	②	①
QUALITY	⑤	④	③	②	①
AUDIO-VISUALS	⑤	④	③	②	①

**2. Learning Objectives**

Were the following learning objectives met?

- At the conclusion of this program, participants should be able to understand current approaches to the treatment of HBV infection, be familiar with current treatment guidelines for HBV infection, including their advantages and limitations and be aware of emerging new therapies for HBV infection under clinical development.  Yes  No

If no, please state reasons:

---



---

**3. General Comments**

- A. Do you feel that the program was fair, balanced, and free of commercial bias?  Yes  No

If no, please state reasons:

---



---

- B. Suggested topics and/or authors/presenters you would like for future educational activities:

---



---

- C. General comments about this educational activity:

---



---



29582

## CME WEB ACTIVITY EVALUATION

### *Treatment Approaches and Guidelines for the Management of HBV Infection*

D. This educational activity has contributed to my professional effectiveness and improved my ability to:

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
Treat/manage patients	⑤	④	③	②	①
Communicate with patients	⑤	④	③	②	①
Manage my clinical practice	⑤	④	③	②	①

#### 4. Faculty Evaluations

Rate the activity for each faculty member listed below.

**Robert P. Perrillo, MD**

	Excellent	Very Good	Good	Fair	Poor
Content of presentation	⑤	④	③	②	①
Ability to convey the subject matter clearly	⑤	④	③	②	①

Do you feel that this presentation was fair, balanced, and free of commercial bias?  Yes  No

### ANSWER SHEET

#### Instructions

In order to complete this program successfully, you must:

- Complete the post-test.
- Complete the program evaluation form.
- Mail or fax your completed answer sheet and program evaluation to:

University of Wisconsin Medical School CME  
2701 International Lane #208  
Madison, WI 53704  
FAX: (608) 240-2151

**In order to ensure scoring, the answer sheet must be received by September 2005.**

- |  |   |
|--|---|
| 1. <input type="radio"/> A <input type="radio"/> B <input type="radio"/> C <input type="radio"/> D | 6. <input type="radio"/> A <input type="radio"/> B <input type="radio"/> C                          |
| 2. <input type="radio"/> True <input type="radio"/> False  | 7. <input type="radio"/> A <input type="radio"/> B <input type="radio"/> C <input type="radio"/> D  |
| 3. <input type="radio"/> A <input type="radio"/> B   | 8. <input type="radio"/> True <input type="radio"/> False   |
| 4. <input type="radio"/> A <input type="radio"/> B <input type="radio"/> C <input type="radio"/> D | 9. <input type="radio"/> True <input type="radio"/> False   |
| 5. <input type="radio"/> A <input type="radio"/> B <input type="radio"/> C <input type="radio"/> D | 10. <input type="radio"/> A <input type="radio"/> B <input type="radio"/> C <input type="radio"/> D |



29582

# CME WEB ACTIVITY EVALUATION *Treatment Approaches and Guidelines for the Management of HBV Infection*

First Name

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

I. Last Name

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Number & Street Address

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

City

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

State

--	--

Zip Code

--	--	--	--	--	--

--	--	--	--

PLEASE FILL IN ONE:

MD     DO     Other \_\_\_\_\_

I claim 

--	--

 · 

--	--

 credits (up to .75 AMA PRA Category 1 credits).

Signature

--

Thank you!